Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial.

[1]  P. Johnston,et al.  Standing the test of time: targeting thymidylate biosynthesis in cancer therapy , 2014, Nature Reviews Clinical Oncology.

[2]  N. Sugimoto,et al.  Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Satoshi Morita,et al.  Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis. , 2013, Journal of the National Cancer Institute.

[4]  A. Nashimoto,et al.  Phase II study of preoperative chemotherapy with S‐1 and cisplatin followed by gastrectomy for clinically resectable type 4 and large type 3 gastric cancers (JCOG0210) , 2013, Journal of surgical oncology.

[5]  T. Yoshikawa,et al.  Body Weight Loss After Surgery is an Independent Risk Factor for Continuation of S-1 Adjuvant Chemotherapy for Gastric Cancer , 2013, Annals of Surgical Oncology.

[6]  Ae Ran Kim,et al.  Changes of Quality of Life in Gastric Cancer Patients After Curative Resection: A Longitudinal Cohort Study in Korea , 2012, Annals of Surgery.

[7]  Wansik Yu,et al.  Changes of Quality of Life after Gastric Cancer Surgery , 2012, Journal of gastric cancer.

[8]  K. Scher,et al.  Under-representation of older adults in cancer registration trials: known problem, little progress. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  K. Bickenbach,et al.  Comparisons of Gastric Cancer Treatments: East vs. West , 2012, Journal of gastric cancer.

[10]  R. Peto,et al.  Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. , 2012, Lancet.

[11]  Y. Bang,et al.  Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial , 2012, The Lancet.

[12]  Joon-Oh Park,et al.  Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Y. Ohashi,et al.  Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  W. Hyung,et al.  Seventh edition of TNM classification for gastric cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  A. Phan,et al.  The role of taxanes in the management of gastroesphageal cancer. , 2011, Journal of gastrointestinal oncology.

[16]  T. Yoshikawa,et al.  Macroscopic tumor size as an independent prognostic factor for stage II/III gastric cancer patients who underwent D2 gastrectomy followed by adjuvant chemotherapy with S-1 , 2011, Gastric Cancer.

[17]  Zhen-ning Wang,et al.  Macroscopic Serosal Classification Predicts Peritoneal Recurrence for Patients with Gastric Cancer Underwent Potentially Curative Surgery , 2011, Annals of Surgical Oncology.

[18]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[19]  Yasuo Ohashi,et al.  Benefit of Adjuvant Chemotherapy for Resectable Gastric Cancer , 2009 .

[20]  A. Valachis,et al.  Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: A meta-analysis. , 2010, Cancer treatment reviews.

[21]  T. Jobo,et al.  Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial , 2009, The Lancet.

[22]  Y. Kodera,et al.  Paclitaxel chemotherapy for the treatment of gastric cancer , 2009, Gastric Cancer.

[23]  N. Boku.  JCOG trials of systemic chemotherapy for unresectable or recurrent gastric cancer , 2009, Gastric Cancer.

[24]  M. Kiechle,et al.  Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials , 2008, Breast Cancer Research.

[25]  R. Gelber,et al.  Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. , 2008, Journal of the National Cancer Institute.

[26]  Y. Ohashi,et al.  Randomized controlled trial of adjuvant uracil–tegafur versus surgery alone for serosa‐negative, locally advanced gastric cancer , 2007, The British journal of surgery.

[27]  Yasuo Ohashi,et al.  Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. , 2007, The New England journal of medicine.

[28]  C. V. D. van de Velde,et al.  Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. , 2006, The New England journal of medicine.

[29]  J. Haerting,et al.  Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Y. Kodera,et al.  Adjuvant chemotherapy with tegafur/uracil (UFT) for gastric cancer. A meta-analysis of centrally randomized clinical trials. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Y. Kodera,et al.  Efficacy of Adjuvant Chemotherapy Using Oral Fluorinated Pyrimidines for Curatively Resected Gastric Cancer: A Meta-Analysis of Centrally Randomized Controlled Clinical Trials in Japan , 2006, Journal of chemotherapy.

[32]  J. Sakamoto,et al.  Pharmacokinetic study of paclitaxel in malignant ascites from advanced gastric cancer patients. , 2006, World journal of gastroenterology.

[33]  Y. Kodera,et al.  A randomized phase III trial of post-operative adjuvant oral fluoropyrimidine versus sequential paclitaxel/oral fluoropyrimidine; and UFT versus S1 for T3/T4 gastric carcinoma: the Stomach Cancer Adjuvant Multi-institutional Trial Group (Samit) Trial. , 2005, Japanese journal of clinical oncology.

[34]  J. Coebergh,et al.  Prognostic impact of increasing age and co-morbidity in cancer patients: a population-based approach. , 2005, Critical reviews in oncology/hematology.

[35]  B. Overmoyer,et al.  Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  A. Nashimoto,et al.  Randomized trial of adjuvant chemotherapy with mitomycin, Fluorouracil, and Cytosine arabinoside followed by oral Fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Barbara L. Smith,et al.  Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Scott A. Hundahl,et al.  Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. , 2001, The New England journal of medicine.

[39]  J. Grem,et al.  Sequence-dependent antagonism between fluorouracil and paclitaxel in human breast cancer cells. , 1999, Biochemical pharmacology.

[40]  A. Nashimoto,et al.  Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial , 1999, The Lancet.

[41]  M. Fujii,et al.  [The optimal period for orally administered fluoropyrimidines as an adjuvant chemotherapy for gastric cancer--a pilot study using 5-FU tablets compared with surgical operation alone]. , 1994, Gan to kagaku ryoho. Cancer & chemotherapy.

[42]  T. Nakajima,et al.  Comparison of 5-fluorouracil with ftorafur in adjuvant chemotherapies with combined inductive and maintenance therapies for gastric cancer. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  J. Sakamoto,et al.  A feasibility study of sequential paclitaxel and S-1 (PTX/S-1) chemotherapy as postoperative adjuvant chemotherapy for advanced gastric cancer , 2006, Gastric Cancer.